Organization
Department of Oncology, Jilin Cancer Hospital, Changchun, China
4 abstracts
Abstract
Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.Org: Zhejiang Cancer Hospital, Hangzhou, China, Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, The First Hospital of China Medical University, Shenyang, China, The Affiliated Cancer Hospital of Xinjiang Medical University, Wulumuqi, China, Second Affiliated Hospital of Nanchang University, Nanchang, China,
Abstract
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.Org: Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Linyi Cancer Hospital, Linyi, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China,
Abstract
A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, West China Hospital, Sichuan University, Chengdu, China, The First Affiliated Hospital of Xiamen University, Xiamen, China, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China, Beijing Cancer Hospital, Beijing, China,
Abstract
A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.Org: Fudan University Shanghai Cancer Center, The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Jilin Cancer Hospital, HUTCHMED Limited,